Summit Therapeutics Other 8-K Filing
Summit Therapeutics received a Complete Response Letter (CRL) from the FDA regarding its Biologics License Application (BLA) for ivonescimab in combination with chemotherapy for certain lung cancer patients. The FDA determined that the BLA cannot be approved in its current form because the progression-free survival benefit did not establish substantial evidence of effectiveness without a statistically significant improvement in overall survival.
- Counterparty
- FDA